Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-engineered lymphocytes in metastatic melanoma
NCT00509288Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2007
- Primary completion
- Jul 2011
- Countries
- 1
01
Overview
A Phase 2 trial of autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes in melanoma, sponsored by National Cancer Institute. Started Jun 2007; status: completed.
02
Drugs
autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00509288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509288.